MDS (MYELODYSPLASTIC SYNDROME)
Clinical trials for MDS (MYELODYSPLASTIC SYNDROME) explained in plain language.
Never miss a new study
Get alerted when new MDS (MYELODYSPLASTIC SYNDROME) trials appear
Sign up with your email to follow new studies for MDS (MYELODYSPLASTIC SYNDROME), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New stem cell method aims to cut transplant risks
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for people with severe aplastic anemia or other bone marrow failure diseases. Doctors give a smaller number of donor white blood cells along with the stem cells to try to reduce serious side effects. Up to 120 patients aged 4…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New stem cell combo could boost survival in blood cancer patients
Disease control Recruiting nowThis study is testing a new way to do stem cell transplants for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). It combines stem cells from a half-matched donor (haploidentical) with cord blood, given at different times. The goal is to help …
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for blood cancer patients: daily pill aims to prevent relapse without transplant
Disease control Recruiting nowThis study tests a daily pill called ivosidenib in about 20 adults with a specific genetic form of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who cannot receive a stem cell transplant. The goal is to see if the drug can keep the cancer from coming ba…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New immune cell boost may shield kids from Post-Transplant infections
Disease control Recruiting nowThis study tests whether adding memory immune cells (CD45RO) to a stem cell transplant can help children fight off dangerous viral and fungal infections after the procedure. The transplant uses donor stem cells that have been stripped of certain cells to prevent graft-versus-host…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for elderly blood cancer patients: experimental transplant prep shows promise
Disease control Recruiting nowThis study tests a new combination of drugs (cladribine, lisaftoclax, busulfan, and others) given before a stem cell transplant in 30 older adults (age 50+) with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. The goal is to see if this approach can re…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Weekly shot may beat daily shots for blood recovery after transplant
Disease control Recruiting nowThis study tests whether a once-weekly injection (romiplostim) can help platelets recover faster and more safely than a daily injection (rhTPO) after a donor stem cell transplant. It includes 66 adults with MDS or severe aplastic anemia. The goal is to reduce bleeding risk and tr…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to free MDS patients from frequent blood transfusions
Disease control Recruiting nowThis Phase II trial tests whether combining luspatercept and darbepoetin alfa can help people with a certain type of lower-risk myelodysplastic syndrome (MDS) need fewer red blood cell transfusions. The study enrolls 60 adults who currently rely on transfusions. Participants rece…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktails aim to tame transplant complications in blood cancer patients
Disease control Recruiting nowThis study tests whether new drug combinations can better prevent graft-versus-host disease (GVHD) in people with blood cancers who receive a stem cell transplant from a mismatched unrelated donor. About 358 participants will get either the standard GVHD prevention or one of two …
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could dead donors provide Life-Saving bone marrow?
Disease control Recruiting nowThis early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE1, PHASE2 • Sponsor: Ossium Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug aims to speed platelet recovery in blood cancer transplants
Disease control Recruiting nowThis study tests a drug called romiplostim N01 in 130 blood cancer patients receiving a stem cell transplant from a half-matched donor. The drug is given weekly for up to 4 weeks to help platelets recover faster, reducing the need for transfusions and bleeding risk. Half the pati…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE1 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough blood cancers? early trial of CG009301 begins
Disease control Recruiting nowThis early-phase trial is testing a new drug called CG009301 in adults with blood cancers like leukemia that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help. About 45 participants will receive the drug by …
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE1 • Sponsor: Cullgen (Shanghai),Inc • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can a broccoli compound help leukemia patients recover faster after transplant?
Disease control Recruiting nowThis study tests whether sulforaphane, a compound found in broccoli sprouts, can help blood cells recover faster after a cord blood transplant in adults with leukemia or related blood cancers. The trial will involve 36 patients and focus on safety and how quickly neutrophils (a t…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for tough blood cancers: ARD103 trial opens
Disease control Recruiting nowThis study tests a new drug called ARD103 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or not responded to standard treatments. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink or c…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Smartwatches could help doctors personalize blood transfusions for cancer patients
Knowledge-focused Recruiting nowThis study is for 80 adults with blood cancers like MDS or AML who are starting treatment. Participants wear a smartwatch and answer questionnaires to track their activity, symptoms, and quality of life. The goal is to help doctors better understand when patients need blood trans…
Matched conditions: MDS (MYELODYSPLASTIC SYNDROME)
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC